Story
Altera Files Confidentially for U.S. Initial Public Offering

Summary
The semiconductor company has submitted a draft registration statement with the U.S. Securities and Exchange Commission, marking a key step in its plan to return to the public markets as a standalone entity.
Altera Corporation has taken a formal step toward becoming a publicly traded company again, announcing it has confidentially submitted a draft registration statement for an initial public offering (IPO) with the U.S. Securities and Exchange Commission.
Details of the Filing
According to the company's statement, the filing was submitted as a draft registration on Form S-1. This is a standard preliminary step for companies planning to list on a U.S. exchange. Key details of the potential offering remain undecided at this stage.
- The number of shares to be offered is currently undetermined.
- The price range for the proposed offering has not yet been set.
The company noted that the IPO is contingent upon the completion of the SEC's review process, as well as prevailing market conditions.
AdContext and Market Implications
A confidential filing allows a company to begin the IPO process and receive feedback from the SEC privately before making its financial information public. This provides flexibility in timing the offering based on market sentiment.
This move marks the next phase in Altera's separation from its parent company, Intel, which acquired the programmable chip maker in 2015. An Altera IPO would re-establish it as a major standalone player in the market for Field-Programmable Gate Arrays (FPGAs), offering investors a pure-play opportunity in a critical semiconductor segment. The listing would be a significant event for the tech sector, closely watched as a gauge of investor appetite for large semiconductor offerings.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.

Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.

Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.

Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.